Benefits
Enhanced Bioavailability vs Standard Curcumin
In a single-dose study, plasma curcuminoid levels reached 807 ng/mL with HydroCurc against 318 ng/mL for unformulated curcumin in the crossover comparison. Eighteen volunteers took part and seven of them continued into the crossover phase, and plasma concentration was the only thing measured, so this shows absorption rather than a health benefit. LipiSperse cold-water-dispersible technology improves intestinal absorption.
Morning Joint Comfort (Partial Result)
In a 2-week trial in 80 adults aged 25 to 70 who reported joint pain, morning pain scores were lower with HydroCurc than with placebo on days 11, 13 and 14. Pain fell in both groups, and there was no difference between groups in evening pain scores, in the SF-36 quality-of-life survey or in the POMS mood survey. No inflammatory marker was measured, and people were recruited for reporting joint pain rather than for a diagnosis of osteoarthritis.
Exercise Recovery: Not Measured Here
None of the studies cited on this page measured exercise, muscle soreness or recovery. Curcumin has been studied for muscle soreness elsewhere, but none of that work is among the references listed here.
Mixes Into Cold Water Without Added Oil
Unlike oil-based curcumin, this powder disperses in cold water, so it can be used in drinks without added oils or fats. This is a formulation feature, not a health effect.
Serum BDNF, an Early Brain Marker
In a 6-week study of 155 healthy adults, 500 mg HydroCurc taken with 18 mg of iron raised serum BDNF, a protein involved in nerve growth, compared with the same iron dose plus placebo. BDNF is a blood marker rather than a measure of memory or thinking, and the increase appeared in only one of the five treatment groups.
Mechanism of action
LipiSperse Cold-Water-Dispersible Technology
LipiSperse is Pharmako Biotechnologies' proprietary delivery system, and it creates cold-water-dispersible particles using food-grade emulsifier and minimal processing. Enables aqueous dispersion.
NF-kB and COX-2 Inhibition
Curcumin inhibits the NF-kB transcription factor and the COX-2 enzyme in laboratory studies. That is the usual explanation for its anti-inflammatory reputation, but it was not measured in any HydroCurc study cited here.
Multiple Inflammatory Pathway Modulation
Curcumin affects: NF-kB, AP-1, JAK-STAT, MAPK, inflammasome activation. These are cell and animal findings for curcumin as a molecule, not results from trials of HydroCurc.
Antioxidant Activity
Curcumin acts as a direct antioxidant and switches on the body's own antioxidant systems (glutathione, the NRF2 pathway) in laboratory models.
Clinical trials
Randomized, double-blind pharmacokinetic comparison of HydroCurc against an unformulated curcumin extract. Eighteen healthy volunteers took a single dose supplying 750 mg of curcuminoids, and 7 of them went on to the crossover phase. Plasma curcuminoid concentration over 24 hours was the only outcome. (Briskey, Sax, Mallard, Rao, Eur J Nutr 2019)
18 healthy men and women; only 7 continued into the crossover phase.
In the crossover phase, plasma curcuminoid concentration reached 807 ng/mL with HydroCurc against 318 ng/mL for the raw curcumin product, about 2.5 times as high. This measured absorption over 24 hours after one dose, so it does not show a health benefit.
Randomized, double-blind, placebo-controlled trial of HydroCurc against placebo for 2 weeks. Pain was self-rated on a visual analogue scale every morning and evening; quality of life used the SF-36 and mood used the POMS. (Briskey, Roche, Rao, Complement Med Res 2022)
80 adults aged 25 to 70 who reported joint pain; recruitment did not require an osteoarthritis diagnosis.
Pain scores fell in both groups over the 2 weeks. Morning scores were significantly lower with HydroCurc than with placebo on days 11, 13 and 14 only. Evening pain scores, the SF-36 and the POMS showed no difference between groups. The trial ran 2 weeks and came from the same research group that ran the manufacturer-funded absorption study.